Skip to main content

Table 1 Correlation with pCR (univariate logistic regression analysis)

From: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

  n events % pCR OR 95% CI p
age (per year) 116 13 - 0.96 0.90-1.01 0.128
biology-based tumor type 116 13     0.044a
   HR+/HER2- 57 1 1.8 1.00   
   HR+/HER2+ 13 3 23.1 16.80 1.59-178.12 0.019
   HR-/HER2+ 13 1 7.7 4.67 0.27-79.96 0.288
   HR-/HER2- 33 8 24.2 17.92 2.13-151.04 0.008
Ki67 106 12     
   <= 20% 85 5 5.9 1.00   
   > 20% 21 7 33.3 8.00 2.22-28.79 0.001
CK5/6 114 13     
   negative 107 10 9.3 1.00   
   positive 7 3 42.9 7.28 1.42-37.22 0.017
COX-2 101 12     
   negative 27 5 18.5 1.00   
   positive 74 7 9.5 0.46 0.13-1.60 0.221
YB-1 106 12     
   negative 71 8 11.3 1.00   
   positive 35 4 11.4 1.02 0.28-3.36 0.980
therapy arm 116 13     
   ddADOC 61 3 4.9 1.00   
   AC-DOC 55 10 18.2 4.30 1.12-16.53 0.034
histology 116 13     0.767a
   ductal-invasive 98 12 12.2 1.00   
   lobular 14 0 0.0 0.00 0.00- - 0.999
   others 4 1 25.0 2.39 0.23-24.86 0.466
grade 116 13     
   G1-2 76 3 3.9 1.00   
   G3 40 10 25.0 8.11 2.09-31.55 0.003
cT 116 27     0.570a
   cT1 9 2 22.2 1.00   
   cT2 87 9 10.3 0.40 0.07-2.25 0.300
   cT3 20 2 10.0 0.39 0.05-3.32 0.388
cN 116 27     
   cN0 79 8 10.1 1.00   
   cN1-2 37 5 13.5 1.39 0.42-4.57 0.591
  1. OR: odds ratio; CI: confidence interval;a: overall significance.